ABION Inc. (KOSDAQ:203400)

South Korea flag South Korea · Delayed Price · Currency is KRW
2,030.00
-115.00 (-5.36%)
At close: May 15, 2026
Market Cap193.27B +4.5%
Revenue (ttm)880.14M +15.9%
Net Income-29.06B
EPS-434.00
Shares Out90.10M
PE Ration/a
Forward PEn/a
Dividendn/a
Ex-Dividend Daten/a
Volume833,022
Average Volume685,856
Open2,145.00
Previous Close2,145.00
Day's Range2,005.00 - 2,215.00
52-Week Range1,911.11 - 7,277.78
Betan/a
RSI31.17
Earnings DateMay 15, 2026

About ABION

ABION Inc. operates as a pharmaceutical biotech Company in South Korea and internationally. The company develops anticancer therapeutic drugs, such as ABN401, a tyrosine kinase inhibitor that is in Phase II clinical trials for treating non-small cell lung cancer, as well as in Phase I clinical trial for breast cancer; ABN501, a human monoclonal antibody that targets claudin 3 for treating solid cancers; ABN201, an antibody cytokine fusion protein to treat solid cancers; and ABN101, a dry powder inhaler as a prophylactic treatment for various re... [Read more]

Founded 2007
Country South Korea
Stock Exchange KOSDAQ
Ticker Symbol 203400
Full Company Profile

Financial Performance

In 2025, ABION's revenue was 880.14 million, an increase of 15.86% compared to the previous year's 759.68 million. Losses were -29.06 billion, -33.00% less than in 2024.

Financial Statements